The protective effect of an immunoactive peptide, D-lactoyl-L-alanyl-r-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine (FK-156) and a related compound, heptanoyl-r-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine (FK-565) was determined in mice with various kinds of microbial infections. FK-156 and FK-565 were given to mice either subcutaneously or orally before challenge. The drugs enhanced significantly the defense of mice against acute systemic infections induced by various extracellular and facultative intracellular organisms, and subcutaneous abscess by Staphylococcus aureus. The protective effect of these drugs against Escherichia coli infection differed considerably depending on the route of administration; FK-156 was only effective by the parenteral route; however, FK-565 was effective by both parenteral and oral routes. After subcutaneous dosing with FK-156, the enhancement of host defense of mice against E. coli infection was more rapid than against Listeria infection. The enhancing effects of FK-156 and FK-565 on host defense of mice against pseudomonal infection was more potent than other immunoactive drugs.
Various microbial products such as BCG1) , Corynebacterium parvum2), endotoxin3), glucan4), krestin5) and phospholipids6) have been shown to enhance host resistance to microbial infection in (Fig. 1)16 ). were inoculated intraperitoneally and intravenously with bacterial suspensions of 0.5 ml, each containing inoculum sizes in a range from LD50 to the minimum lethal dose. In the case of salmonellosis, ddY strain mice (4 weeks old) were used. The mice were fasted overnight and challenged orally with Salmonella enteritidis strain FP233 at 10 cfu/mouse, 3 times at 6-hour intervals. The protective effect was estimated by the number of mice surviving after 4 to 14 days of observation. For subcutaneous staphylococcal abscess, the mice were inoculated subcutaneously with 2.0 x 10' cfu/site on the lower back for the FK-156-and 3.4 x 107 cfu/site for the FK-565-treated mice. The skin of the inoculation site was excised 5 days after challenge and homogenized in saline with a Polytron. Viable cell counts were determined by plating on agar and counting colony forming units (cfu).
Materials and Methods

Drugs
FK-l56 (D-lactoyl-L-alanyl-7-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine) and FK-565 (hepta- noyl-r-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine)
Results
Acute Systemic Infection
The effect of FK-156 and FK-565 on host-defense ability of mice against microbial infection was evaluated. As shown in Table 2 , survival rates in animals with microbial infection due to extracellular organisms, such as Escherichia coli strain 22, Klebsiella pneumoniae strain 57, Serratia marcescens strain 32 and Pseudomonas aeruginosa strain 97 were 70 to 100% when FK-156 was given in a single subcutaneous dose of 1 mg/kg 4 days or I day before challenge, and 40 to 80 % when FK-565 was given orally in a dose of 0.1 mg/kg 6, 5, 4 and 1 day before challenge. In addition, both peptides, FK-156 and FK-565 were effective against microbial infection due to facultative intracellular parasites such as Listeria and Salmonella. The survival rate of mice given FK-156 was 40% for Listeria monocytogenes strain FP566 and 50% and 70% respectively for intravenous and oral challenge with Salmonella enteritidis strain FP233.
The survival rates of mice given FK-565 were 80 to 90 % for these 2 bacterial infections, whereas survival rates for mice infected with Candida albicans strain FP-633 were 30 % for FK-156 and 80 % for FK-565. The host defense ability of mice given the peptides was enhanced against all strains tested, although the protective effect varied among the challenge organisms. A similar decrease of the viable cell count was also seen when the drug was given 1 or 3 days before challenge. A significant decrease of viable cell count at the site of abscess was also observed when FK-565 was given orally to mice at 7 or 3 days or 1 day before challenge.
Effect of Various Routes of Dosing
The effects of different routes of dosing were compared in mice with E. coli infection (Table 1) . A single parenteral dose of 0.1 or 1 mg/kg of the drugs was given to mice 4 days before challenge, or the drugs of 0.1 or I mg/kg/day were given orally to mice 4 times (at 6, 5, 4 days and I day) before challenge.
Intraperitoneally administered FK-156 (1 mg/kg) was the most effective against E. coil infection, followed by the intravenous and subcutaneous routes, whereas oral dosing 4 times before challenge was not effective. With 0.1 mg/kg, no marked difference was found among the parenteral routes used. FK-565
(1 mg/kg) by the intraperitoneal route was also the most effective, followed by the oral, intravenous and subcutaneous routes. With 0.1 mg/kg, the intraperitoneal route was also more effective than the other routes.
Time-dependence in Protective Effect of FK-156 on E. coil and Listeria Infection
A single intraperitoneal dose of FK-156 (1 mg/kg) was given to mice at different intervals before challenge with E. coli strain 22 or L. monocytogenes strain FP566. Table 3 shows that the resistance of mice to E. co/i infection was rapidly enhanced and persisted well. The survival rate was as high as 40% when FK-156 was given 7 days before challenge and as high as 90% when the drug was given on the day before challenge. However, as long as 4 days was needed to enhance the protective ability of mice against Listeria infection. Mice were given intraperitoneally 1 mg/kg of FK-156, and inoculated intraperitoneally 4.8 x 10--cfu/mouse with E. coil No. 22 and 7.5 x 107 cfu/ mouse of L. monocytogenes FP566. These immunostimulants were subcutaneously 7 or 1 day before challenge with P. aeruginosa.
Comparison with Other Immunostimulants in Pseudomonal Infection
The test drugs were given in a single subcutaneous dose of I or 0.1 mg/kg to mice 7 days or 1 day before challenge with P. aeruginosa.
The protective effect and onset of effect of immunostimulants varied by drug and time of dosing.
However, the protective effect of both FK-156 and FK-565 was the most potent of all the test drugs after both dosing times and did not vary in time of onset.
Therefore, the defensive ability of mice against pseudomonal infection was rapidly enhanced and persisted until the end of the study.
Discussion
In spite of the advent of potent new antibiotics, we still face many problems in the chemotherapy of infection in immunocompromised patients. Therapeutic attempts to enhance overall host resistance to infection by restoring impaired defense mechanisms have been carried out in many experimental models.
Various microbial products such as BCGI>, Corynebacterium parvum2), endotoxin3), gucan4), krestin5), phospholipid6) have been shown to enhance host resistance to infection. However, most of these substances are macromolecular, insoluble, pyrogenic and not well defined chemically. Recently, a synthetic compound, MDP has been shown to possess the minimal active structure essential for eliciting the effect of the whole mycobacterial cell contained in Freund's complete adjuvant.'17-19) MDP and its analogues have also been shown to increase nonspecific resistance against infection8-10). FK-156 used in this study is an acyl peptide, composed of D-lactic acid and four amino acids, Lalanine, D-glutamic acid, a,s-meso-diaminopimelic acid and glycine. It was first extracted from the fermentation broth of S. olivaceogriseus11--15>. However, the compound has been successfully synthesized chemically. Its analogue, FK-565, is composed of heptanoic acid and the three amino acids, D-glutamic acid, a,s-meso-diaminopimelic acid and D-alanine16). 
